CoH's specialty is discovering new molecules and their mechanisms of action in the m6A mRNA space. Full stop. But they are superb at doing that. They run rings around RAC.
RAC's specialties are resurrecting old chemotherapy molecules, developing new formulations of old drugs, developing companion diagnostic tests, conducting preclinical trials (using contractors), conducting Phase 2 trials (using CROs).
Neither CoH nor RAC are good at Phase 3 trials or commercialisation. And they both know it.
IGF2BP2 - Jianjun Chen's new mRNA target, page-11
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
0.010(0.64%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.64 | $1.55 | $134.0K | 84.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6283 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 6559 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |